

The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2017-1456
Date:	23 March 2017
Product Name:	Ustekinumab/ Golimumab
Therapeutic Area:	Immunology
Product Class:	mAB anti-IL12 / anti-IL23 Tumor necrosis factor (TNF) blocker
Condition(s) Studied:	Psoriatic Arthritis
Protocol Number(s) and Title(s):	<p>NCT01009086 - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis</p> <p>NCT01077362- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Ustekinumab, a Fully Human Anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNFalpha Agent(s)</p> <p>NCT00265096- A Multicenter, Randomized, Double-blind, Placebo controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Psoriatic Arthritis</p>
Part 2: Data Availability	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	N/A or add comments if answered No.
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	N/A or add comments if answered No.
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	N/A or add comments if answered No.
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	N/A or add comments if answered No.
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	N/A or add comments if answered No.
Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes

The YODA Project
Research Proposal Due Diligence Assessment

Part 4: Proposal Review	
Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	